MX370139B - Pirofosfato ferrico soluble (pfs) para usarse en el tratamiento de anemiay/o de la deficiencia de hierro. - Google Patents
Pirofosfato ferrico soluble (pfs) para usarse en el tratamiento de anemiay/o de la deficiencia de hierro.Info
- Publication number
- MX370139B MX370139B MX2015009968A MX2015009968A MX370139B MX 370139 B MX370139 B MX 370139B MX 2015009968 A MX2015009968 A MX 2015009968A MX 2015009968 A MX2015009968 A MX 2015009968A MX 370139 B MX370139 B MX 370139B
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- iron deficiency
- ferric pyrophosphate
- soluble ferric
- treating iron
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/42—Phosphorus; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1816—Erythropoietin [EPO]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Inorganic Chemistry (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Obesity (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Nutrition Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Molecular Biology (AREA)
Abstract
La presente invención se refiere a el uso de pirofosfato férrico soluble para tratar la anemia y/o la deficiencia de hierro, y para reducir o eliminar la dosis de un agente estimulante de la eritropoyesis para elevar o mantener los niveles de hemoglobina en el rango objetivo en un sujeto que sufra de anemia, lo cual consiste en administrar pirofosfato férrico soluble en una cantidad efectiva para mantener los niveles Hgb en el sujeto.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361759531P | 2013-02-01 | 2013-02-01 | |
PCT/US2014/014341 WO2014121155A1 (en) | 2013-02-01 | 2014-02-01 | Methods of treating iron deficiency with soluble ferric pyrophosphate |
Publications (2)
Publication Number | Publication Date |
---|---|
MX2015009968A MX2015009968A (es) | 2016-03-11 |
MX370139B true MX370139B (es) | 2019-12-03 |
Family
ID=50097899
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2015009968A MX370139B (es) | 2013-02-01 | 2014-02-01 | Pirofosfato ferrico soluble (pfs) para usarse en el tratamiento de anemiay/o de la deficiencia de hierro. |
Country Status (20)
Country | Link |
---|---|
US (3) | US20150366907A1 (es) |
EP (2) | EP3789034A1 (es) |
JP (3) | JP2016507527A (es) |
KR (1) | KR102236714B1 (es) |
CN (2) | CN104936609B (es) |
AU (3) | AU2014212127A1 (es) |
BR (1) | BR112015018549A8 (es) |
CA (1) | CA2900043A1 (es) |
CL (1) | CL2015002171A1 (es) |
EA (1) | EA032407B1 (es) |
HK (1) | HK1215185A1 (es) |
IL (1) | IL240257A0 (es) |
MX (1) | MX370139B (es) |
NI (1) | NI201500100A (es) |
PE (1) | PE20151751A1 (es) |
PH (1) | PH12015501708A1 (es) |
SG (1) | SG11201506022VA (es) |
TW (1) | TW201517913A (es) |
WO (1) | WO2014121155A1 (es) |
ZA (1) | ZA201506364B (es) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2941479T3 (es) | 2012-06-15 | 2023-05-23 | Symrise Ag | Composiciones que comprenden agentes que promueven la biosíntesis de hialuronano |
US20160250254A1 (en) * | 2013-11-05 | 2016-09-01 | Rockwell Medical, Inc. | Methods of reducing doses of erythropoietin stimulating agents in hyporesponsive patients |
SG10202107245UA (en) * | 2015-09-04 | 2021-08-30 | Rockwell Medical Inc | Solid soluble ferric pyrophosphate formulations, kits, and methods using the same |
CN106581053A (zh) * | 2015-10-20 | 2017-04-26 | 华仁药业股份有限公司 | 一种具有补铁功能的腹膜透析液 |
WO2020040294A1 (ja) * | 2018-08-24 | 2020-02-27 | 国立大学法人横浜国立大学 | 投与管理装置、投与管理方法、プログラム |
US11278651B2 (en) * | 2018-10-17 | 2022-03-22 | Gambro Lundia Ab | Membrane and device for treating restless leg syndrome |
CN110063965A (zh) * | 2019-06-04 | 2019-07-30 | 吉林省富生医疗器械有限公司 | 一种血液透析浓缩物 |
EP4103595A4 (en) * | 2020-02-11 | 2024-06-26 | Quest Diagnostics Investments LLC | SYSTEM FOR DETERMINING AN UNDERLYING CAUSE OF ANEMIA |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6779468B1 (en) | 1997-08-07 | 2004-08-24 | Ajay Gupta | Method and pharmaceutical composition for iron delivery in hemodialysis and peritoneal dialysis patients |
US6689275B1 (en) | 1996-12-31 | 2004-02-10 | Ajay Gupta | Method and pharmaceutical composition for replacing iron losses in dialysis patients |
ATE311180T1 (de) * | 1996-12-31 | 2005-12-15 | Ajay Gupta | Verfahren und pharmazeutische zusammensetzung zur verabreichung von eisen an hämodialyse- oder peritonealdialyse-patienten |
US6779648B2 (en) * | 2000-07-13 | 2004-08-24 | Psi Sales, Inc. | 360 Degree rotatable lifter arm for log singulator |
JP2005068055A (ja) * | 2003-08-22 | 2005-03-17 | Fujiyakuhin Co Ltd | 無機元素含有水性コロイド分散液 |
US7857977B2 (en) * | 2005-07-12 | 2010-12-28 | Rockwell Medical Technologies, Inc. | Packaging of ferric pyrophosphate for dialysis |
DK1973552T3 (en) * | 2005-12-23 | 2017-08-07 | Ajay Gupta | Parenteral nutritional composition containing iron |
US7816404B2 (en) * | 2007-07-20 | 2010-10-19 | Rockwell Medical Technologies, Inc. | Methods for the preparation and use of ferric pyrophosphate citrate chelate compositions |
US8178709B2 (en) * | 2009-07-21 | 2012-05-15 | Biolink Life Sciences, Inc. | Iron preparation suitable for pharmaceutical formulation and process for the preparation thereof |
KR20140026354A (ko) * | 2011-01-07 | 2014-03-05 | 메리온 리서치 Ⅲ 리미티드 | 경구 투여용 철의 제약 조성물 |
-
2014
- 2014-02-01 KR KR1020157022737A patent/KR102236714B1/ko active IP Right Grant
- 2014-02-01 WO PCT/US2014/014341 patent/WO2014121155A1/en active Application Filing
- 2014-02-01 EA EA201591424A patent/EA032407B1/ru unknown
- 2014-02-01 EP EP20185823.0A patent/EP3789034A1/en not_active Withdrawn
- 2014-02-01 EP EP14704273.3A patent/EP2950806B1/en active Active
- 2014-02-01 JP JP2015556190A patent/JP2016507527A/ja active Pending
- 2014-02-01 CN CN201480003130.9A patent/CN104936609B/zh active Active
- 2014-02-01 CA CA2900043A patent/CA2900043A1/en not_active Abandoned
- 2014-02-01 SG SG11201506022VA patent/SG11201506022VA/en unknown
- 2014-02-01 MX MX2015009968A patent/MX370139B/es active IP Right Grant
- 2014-02-01 BR BR112015018549A patent/BR112015018549A8/pt not_active Application Discontinuation
- 2014-02-01 PE PE2015001600A patent/PE20151751A1/es unknown
- 2014-02-01 AU AU2014212127A patent/AU2014212127A1/en not_active Abandoned
- 2014-02-01 CN CN201710166250.6A patent/CN107007624A/zh active Pending
- 2014-02-01 US US14/765,111 patent/US20150366907A1/en not_active Abandoned
- 2014-02-05 TW TW103103727A patent/TW201517913A/zh unknown
-
2015
- 2015-07-30 IL IL240257A patent/IL240257A0/en unknown
- 2015-07-31 NI NI201500100A patent/NI201500100A/es unknown
- 2015-07-31 PH PH12015501708A patent/PH12015501708A1/en unknown
- 2015-08-03 CL CL2015002171A patent/CL2015002171A1/es unknown
- 2015-08-31 ZA ZA2015/06364A patent/ZA201506364B/en unknown
-
2016
- 2016-03-21 HK HK16103233.3A patent/HK1215185A1/zh not_active IP Right Cessation
-
2017
- 2017-11-10 US US15/809,734 patent/US20180280432A1/en not_active Abandoned
-
2018
- 2018-12-12 AU AU2018278891A patent/AU2018278891B2/en not_active Ceased
-
2019
- 2019-06-18 JP JP2019112699A patent/JP2019151669A/ja active Pending
-
2020
- 2020-05-18 US US16/877,086 patent/US20200276232A1/en not_active Abandoned
- 2020-12-09 AU AU2020286223A patent/AU2020286223A1/en not_active Abandoned
-
2021
- 2021-07-26 JP JP2021121654A patent/JP2021169525A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12015501708A1 (en) | Methods of treating iron deficiency with soluble ferric pyrophosphate | |
PH12017502391A1 (en) | Compositions and methods for inhibiting arginase activity | |
MA40437A (fr) | Méthodes de traitement du cancer faisant appel à des inhibiteurs de tigit et à des agents anticancéreux | |
MX2021014709A (es) | Composiciones para usarse en el incremento de los niveles de globulos rojos y el tratamiento de enfermedad de celulas falciformes. | |
MX2016002645A (es) | Tratamiento combinado para tratar el glioblastoma. | |
MX2017016491A (es) | Metodos para tratar malignidad hematologica usando terapia combinada de nanoparticulas de inhibidor de objetivo mamifero de la rapamicina (mtor). | |
MX2020011783A (es) | Terapia de combinacion que involucra anticuerpos contra claudina 18.2 para tratamiento de cancer. | |
MX2016007351A (es) | Terapia de combinacion para tratar cancer. | |
NZ719049A (en) | Cancer treatment with combination of plinabulin and taxane | |
MX2015011783A (es) | Metodos para tratar tumores solidos pediatricos. | |
MY162903A (en) | Methods of treatment of pancreatic cancer | |
MX369691B (es) | Inhibidores de glutaminasa y métodos de empleo. | |
MX360189B (es) | Terapia de combinacion para el tratamiento de glioblastoma. | |
BR112015023020A2 (pt) | combinação de inibidor de egfr t790m e inibidor de egfr para o tratamento de câncer pulmonar de células não-pequenas | |
MX2015014599A (es) | Terapia de combinacion que comprende un inhibidor de tor cinasa y un analogo de citidina para tracar cancer. | |
PH12016500140A1 (en) | Heterobicycloaryl rorc2 inhibitors and methods of use thereof | |
NZ702087A (en) | Pharmaceutical compositions and treatment of mastitis | |
IN2014MN01945A (es) | ||
NZ707090A (en) | Synthetic lethality and the treatment of cancer | |
MX2018010223A (es) | Terapia combinada para tratamiento de cancer de ovario. | |
MY191932A (en) | Chitosan-derived compositions | |
MX2017015532A (es) | Terapia de combinacion pac-1. | |
MX2015010296A (es) | Tratamiento de formas progresivas de esclerosis multiple con laquinimod. | |
MX2014010714A (es) | Terapia de combinacion de procaspasa para gliobastoma. | |
NZ713129A (en) | Oxprenolol compositions for treating cancer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |